Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Strides Pharma Science Ltd ( (IN:STAR) ) has issued an announcement.
Strides Pharma Inc., the U.S. subsidiary of Strides Pharma Science Limited, has received a closure report (Establishment Inspection Report) from the USFDA for its formulations facility at Chestnut Ridge, New York, following an inspection conducted in December 2025 that covered cGMP compliance and a pre-approval review of its drug–device combination capabilities for recently filed nasal spray products. The inspection was classified as Voluntary Action Indicated, confirming that the issues noted on Form 483 have been satisfactorily addressed and the inspection closed, thereby reinforcing the regulatory standing of the Chestnut Ridge site, which supplies a range of formulations to the U.S. market and underpinning Strides’ U.S. business momentum and near-term growth prospects, while underscoring its emphasis on regulatory compliance and high-quality manufacturing for global markets.
More about Strides Pharma Science Ltd
Strides Pharma Science Limited is a global pharmaceutical company headquartered in Bengaluru, India, listed on the BSE and NSE, and focused on regulated markets with an “in Africa for Africa” strategy and an institutional business serving donor-funded markets. The company operates manufacturing facilities in India, Italy, Kenya and the United States, specializing in difficult-to-manufacture products, including liquids, gels, hormones, modified-release products and controlled substances, which it supplies to over 100 countries.
Average Trading Volume: 23,692
Technical Sentiment Signal: Buy
Current Market Cap: 77.02B INR
Find detailed analytics on STAR stock on TipRanks’ Stock Analysis page.